Join the Cibinqo group to help and get support from people like you.
Cibinqo News
Abrocitinib Effective, Tolerated for Prurigo Nodularis, Chronic Pruritus
TUESDAY, June 25, 2024 – For patients with prurigo nodularis (PN) and chronic pruritus of unknown origin (CPUO), abrocitinib, a Janus kinase 1 inhibitor, is effective and well tolerated, according...
FDA Approves Pfizer's Supplemental New Drug Application for Cibinqo (abrocitinib) to Include Adolescents with Moderate-to-Severe Atopic Dermatitis
Label expansion for Cibinqo provides new systemic oral option for adolescents (12 to
FDA Approves Cibinqo (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
NEW YORK--(BUSINESS WIRE) January 14, 2022 – Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Cibinqo® (abrocitinib), an oral, ...
Further information
Related condition support groups
Contact Dermatitis, Atopic Dermatitis